Nowadays, AB-FUBINACA has become a topic of general interest to many people around the world. Its relevance and significance have generated great debate and analysis in today's society. From different perspectives, AB-FUBINACA has captured the attention of experts and fans, becoming a recurring topic in conversations, discussions and research. Whether due to its impact on culture, economy, politics or on a personal level, AB-FUBINACA continues to be a point of constant attention and study. In this article, we will thoroughly explore the meaning and importance of AB-FUBINACA, as well as its impact on modern society.
AB-FUBINACA (AMB-FUBINACA[2]) is a psychoactivedrug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2.[3][4][5] It was originally developed by Pfizer in 2009 as an analgesic medication[6] but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan,[7] along with a related compound AB-PINACA, which had not previously been reported.
Its use has been linked to hospitalizations and deaths.[8][9]
Since October 2015 AB-FUBINACA is a controlled substance in China.[13]
Others
In December 2019, the UNODC announced scheduling recommendations placing AB-FUBINACA as a controlled research chemical into Schedule II.[14]
101789
Mass overdoses due to adulterated K2
On August 15, 2018, 70 people within the city of New Haven, Connecticut, started overdosing near Yale University campus.[15] By the end of the week, the total number of overdosed had risen to over 100 people needing transport to local emergency rooms. Three men were arrested, charged as drug dealers selling synthetic cannabis which contained AB-FUBINACA.[16][17][18] First responders concluded that the overdoses were caused by opiate adulterants, as victims responded to Narcan.[19] Almost all of the overdoses occurred on the New Haven Green, a large downtown park that is heavily traveled and very popular with the homeless population. There have been no deaths associated with these overdoses; however, several victims were in critical or life-threatening condition for a period of time.[20]
^Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID36346325.
^Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID26134475.
^Vikingsson S, Gréen H, Brinkhagen L, Mukhtar S, Josefsson M (September 2016). "Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry". Drug Testing and Analysis. 8 (9): 950–6. doi:10.1002/dta.1896. PMID26560240.
^Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (January 2013). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology. 31 (1): 93–100. doi:10.1007/s11419-012-0171-4. S2CID25242453.
^Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–7. doi:10.1056/NEJMp1505328. PMID26154784.
^Klavž J, Gorenjak M, Marinšek M (August 2016). "Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC". Forensic Science International. 265: 121–4. doi:10.1016/j.forsciint.2016.01.018. PMID26890319.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 30 September 2015.